Current treatment approaches to early childhood medulloblastoma

Expert Review of Neurotherapeutics

Volumn 6, Issue 8, 2006, Pages 1211-1221

  Rutkowski, Stefan ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Brain tumor; Chemotherapy; Children; High dose chemotherapy; Infants; Medulloblastoma; Methotrexate; Neurocognition; Sequelae; Treatment

Indexed keywords

ALKYLATING AGENT; BIOLOGICAL MARKER; BUSULFAN; CARBOPLATIN; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GLUCOCORTICOID; IFOSFAMIDE; LOMUSTINE; MAFOSFAMIDE; MELPHALAN; METHOTREXATE; PREDNISONE; PROCARBAZINE; THIOTEPA; TOPOTECAN; VINCRISTINE; VINCRISTINE SULFATE;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CEREBROSPINAL FLUID; CHILDHOOD CANCER; CLINICAL TRIAL; COGNITIVE DEFECT; GROWTH INHIBITION; HISTOPATHOLOGY; HUMAN; INTELLIGENCE QUOTIENT; LEUKOENCEPHALOPATHY; MEDULLOBLASTOMA; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTOPERATIVE PERIOD; PROGNOSIS; REVIEW; RISK ASSESSMENT; SECOND CANCER; SKULL IRRADIATION; TREATMENT OUTCOME;

BRAIN STEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; HUMANS; INCIDENCE; MEDULLOBLASTOMA; MONITORING, INTRAOPERATIVE;

EID: 33747165307     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.6.8.1211     Document Type: Review

References (80)

1. Kaatsch P, Rickert CH, Kuhl J et al. Population-based epidemiologic data on brain tumors in German children. Cancer 92, 3155-3164 (2001).
2. McNeil DE, Cote TR, Clegg L, Rorke LB. Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: a SEER update. Surveillance epidemiology and end results. Med. Pediatr. Oncol. 39, 190-194 (2002).
3. Raffel C. Medulloblastoma: molecular genetics and animal models. Neoplasia 6, 310-322 (2004).
4. Chang CH, Housepian EM, Herbert C Jr. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology 93, 1351-1359 (1969).
5. Rorke LB, Packer RJ, Biegel JA. Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: definition of an entity. J. Neurosurg. 85, 56-65 (1996).
6. Packer RJ, Goldwein J, Nicholson HS et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children's Cancer Group Study. J. Clin. Oncol. 17, 2127-2136 (1999).
7. Kuhl J, Muller HL, Berthold F et al. Preradiation chemotherapy of children and young adults with malignant brain tumors: results of the German pilot trial HIT'88/'89. Klin. Padiatr. 210, 227-233 (1998).
8. Kortmann RD, Kuhl J, Timmermann B et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91. Int. J. Radiat. Oncol. Biol. Phys. 46, 269-279 (2000).
9. Taylor RE, Bailey CC, Robinson K et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study. J. Clin. Oncol. 21, 1581-1591 (2003).
10. Zeltzer PM, Boyett JM, Finlay JL et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized Phase III study. J. Clin. Oncol. 17, 832-845 (1999).
11. Packer RJ, Rood BR, MacDonald TJ. Medulloblastoma: present concepts of stratification into risk groups. Pediatr. Neurosurg. 39, 60-67 (2003).
12. Kellie SJ. Chemotherapy of central nervous system tumours in infants. Childs Nerv. Syst. 15, 592-612 (1999). • Detailed, hypothesis-based review of treatment approaches for young children with brain tumors.
13. Evans AE, Jenkin RD, Sposto R et al. The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J. Neurosurg. 72, 572-582 (1990).
14. Kiltie AE, Lashford LS, Gattamaneni HR. Survival and late effects in medulloblastoma patients treated with craniospinal irradiation under three years old. Med. Pediatr. Oncol. 28, 348-354 (1997).
15. Hoppe-Hirsch E, Brunet L, Laroussinie F et al. Intellectual outcome in children with malignant tumors of the posterior fossa: influence of the field of irradiation and quality of surgery. Childs Nerv. Syst. 11, 340-345 (1995).
16. Palmer SL, Goloubeva O, Reddick WE et al. Patterns of intellectual development among survivors of pediatric medulloblastoma: a longitudinal analysis. J. Clin. Oncol. 19, 2302-2308 (2001).
17. Bouffet E, Bernard JL, Frappaz D et al. M4 protocol for cerebellar medulloblastoma: supratentorial radiotherapy may not be avoided. Int. J. Radiat. Oncol. Biol. Phys. 24, 79-85 (1992).
18. Hong TS, Mehta MP, Boyett JM et al. Patterns of treatment failure in infants with primitive neuroectodermal tumors who were treated on CCG-921: a Phase III combined modality study. Pediatr. Blood Cancer 45, 676-682 (2005).
19. Bailey CC, Gnekow A, Wellek S et al. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Med. Pediatr. Oncol. 25, 166-178 (1995).
20. Saran FH, Driever PH, Thilmann C et al. Survival of very young children with medulloblastoma (primitive neuroectodermal tumor of the posterior fossa) treated with craniospinal irradiation. Int. J. Radiat. Oncol. Biol. Phys. 42, 959-967 (1998).
21. Attard-Montalto S, Plowman N, Breatnach F et al. Is there a danger in delaying radiotherapy in childhood medulloblastoma? Br. J. Radiol. 66, 807-813 (1993).
22. Tarbell NJ, Loeffler JS, Silver B et al. The change in patterns of relapse in medulloblastoma. Cancer 68, 1600-1604 (1991).
23. Kovnar EH, Kellie SJ, Horowitz ME et al. Preirradiation cisplatin and etoposide in the treatment of high-risk medulloblastoma and other malignant embryonal tumors of the central nervous system: a Phase II study. J. Clin. Oncol. 8, 330-336 (1990).
24. Loeffler JS, Kretschmar CS, Sallan SE et al. Preradiation chemotherapy for infants and poor prognosis children with medulloblastoma. Int. J. Radiat. Oncol. Biol. Phys. 15, 177-181 (1988).
25. Guruangan S, Dunkel IJ, Goldman S et al. Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors. J. Clin. Oncol. 16, 2486-2493 (1998).
26. Kalifa C, Valteau D, Pizer B et al. High-dose chemotherapy in childhood brain tumours. Childs Nerv. Syst. 15, 498-505 (1999).
27. Levin VA, Patlak CS, Landahl HD. Heuristic modeling of drug delivery to malignant brain tumors. J. Pharmacokinet. Biopharm. 8, 257-296 (1980).
28. van Eys J, Chen T, Moore T et al. Adjuvant chemotherapy for medulloblastoma and ependymoma using i.v. vincristine, intrathecal methotrexate, and intrathecal hydrocortisone: a Southwest Oncology Group Study. Cancer Treat. Rep. 65, 681-684 (1981).
29. Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N. Engl. J. Med. 293, 161-166 (1975).
30. Bleyer WA, Poplack DG, Simon RM. "Concentration x time" methotrexate via a subcutaneous reservoir: a less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms. Blood 51, 835-842 (1978). • Important pharmacokinetic findings regarding intracerebrospinal fluid application of methotrexate.
31. Kerr JZ, Berg S, Blaney SM. Intrathecal chemotherapy. Crit. Rev. Oncol. Hematol. 37, 227-236 (2001).
32. Bleyer WA, Poplack DG. Intraventricular versus intralumbar methotrexate for central-nervous-system leukemia: prolonged remission with the Ommaya reservoir. Med. Pediatr. Oncol. 6, 207-213 (1979).
33. Fleischhack G, Jaehde U, Bode U. Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis. Clin. Pharmacokinet. 44, 1-31 (2005). • Comprehensive review on pharmacokinetics of agents available for intrathecal application.
34. Blaney SM, Balis FM, Berg S et al. Intrathecal mafosfamide: a preclinical pharmacology and Phase I trial. J. Clin. Oncol. 23, 1555-1563 (2005).
35. Kalifa C, Grill J. The therapy of infantile malignant brain tumors: current status? J. Neuro-oncol. 75, 279-285 (2005).
36. Warren KE, Packer RJ. Current approaches to CNS tumors in infants and very young children. Expert Rev. Neurother. 4, 681-690 (2004).
37. van Eys J, Cangir A, Coody D, Smith B. MOPP regimen as primary chemotherapy for brain tumors in infants. J. Neurooncol. 3, 237-243 (1985).
38. Ater JL, van Eys J, Woo SY et al. MOPP chemotherapy without irradiation as primary postsurgical therapy for brain tumors in infants and young children. J. Neurooncol. 32, 243-252 (1997).
39. Horowitz ME, Mulhern RK, Kun LE et al. Brain tumors in the very young child. Postoperative chemotherapy in combined-modality treatment. Cancer 61, 428-434 (1988).
40. Geyer R, Levy M, Berger MS et al. Infants with medulloblastoma: a single institution review of survival. Neurosurgery 29, 707-710 (1991).
41. Lashford LS, Campbell RH, Gattamaneni HR et al. An intensive multiagent chemotherapy regimen for brain tumours occurring in very young children. Arch. Dis. Child 74, 219-223 (1996).
42. Kretschmar CS, Tarbell NJ, Kupsky W et al. Pre-irradiation chemotherapy for infants and children with medulloblastoma: a preliminary report. J. Neurosurg. 71, 820-825 (1989).
43. Gajjar A, Mulhern RK, Heideman RL et al. Medulloblastoma in very young children: outcome of definitive craniospinal irradiation following incomplete response to chemotherapy. J. Clin. Oncol. 12, 1212-1216 (1994).
44. Geyer JR, Zeltzer PM, Boyett JM et al. Survival of infants with primitive neuroectodermal tumors or malignant ependymomas of the CNS treated with eight drugs in 1 day: a report from the Childrens Cancer Group. J. Clin. Oncol. 12, 1607-1615 (1994).
45. Hartsell WF, Gajjar A, Heideman RL et al. Patterns of failure in children with medulloblastoma: effects of preirradiation chemotherapy. Int. J. Radiat. Oncol. Biol. Phys. 39, 15-24 (1997).
46. Duffner PK, Horowitz ME, Krischer JP et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N. Engl. J. Med. 328, 1725-1731 (1993). • Large study on young children with CNS tumors.
47. Walter AW, Mulhern RK, Gajjar A et al. Survival and neurodevelopmental outcome of young children with medulloblastoma at St Jude Children's Research Hospital. J. Clin. Oncol. 17, 3720-3728 (1999).
48. Duffner PK, Horowitz ME, Krischer JP et al. The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience. Neuro-oncol. 1, 152-161 (1999).
49. White L, Kellie S, Gray E et al. Postoperative chemotherapy in children less than 4 years of age with malignant brain tumors: promising initial response to a VETOPEC-based regimen. A Study of the Australian and New Zealand Children's Cancer Study Group (ANZCCSG). J. Pediatr. Hematol. Oncol. 20, 125-130 (1998).
50. Geyer JR, Sposto R, Jennings M et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. J. Clin. Oncol. 23, 7621-7631 (2005).
51. Kuhl J, Beck J, Bode U et al. Delayed radiation therapy after postoperative chemotherapy in children less than 3 years of age with medulloblastoma. Results of the trial HIT-SKK'87, and preliminara results of the pilot trial HIT-SKK'92. Med. Pediatr. Oncol. 25, 250 (1995).
52. Rutkowski S, Bode U, Deinlein F et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N. Engl. J. Med. 352, 978-986 (2005). • Paper reporting a new treatment strategy consisting of systemic and intraventricular chemotherapy alone.
53. Mason WP, Grovas A, Halpern S et al. Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. J. Clin. Oncol. 16, 210-221 (1998).
54. Chi SN, Gardner SL, Levy AS et al. Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. J. Clin. Oncol. 22, 4881-4887 (2004). • Promising response rates by intensified treatment strategies in young children with metastatic medulloblastoma.
55. Grill J, Sainte-Rose C, Jouvet A et al. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol. 6, 573-580 (2005). • The concept of high-dose chemotherapy and radiotherapy as an efficient salvage strategy in young children with medulloblastoma.
56. Grill J, Kieffer V, Kalifa C. Measuring the neuro-cognitive side-effects of irradiation in children with brain tumors. Pediatr. Blood Cancer 42, 452-456 (2004).
57. Silber JH, Radcliffe J, Peckham V et al. Whole-brain irradiation and decline in intelligence: the influence of dose and age on IQ score. J. Clin. Oncol. 10, 1390-1396 (1992).
58. Duffner PK, Cohen ME, Thomas PR, Lansky SB. The long-term effects of cranial irradiation on the central nervous system. Cancer 56, 1841-1846 (1985).
59. Duffner PK. Long-term effects of radiation therapy on cognitive and endocrine function in children with leukemia and brain tumors. Neurologist 10, 293-310 (2004).
60. Mulhern RK, Merchant TE, Gajjar A et al. Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol. 5, 399-408 (2004).
61. Fouladi M, Gilger E, Kocak M et al. Intellectual and functional outcome of children 3 years old or younger who have CNS malignancies. J. Clin. Oncol. 23, 7152-7160 (2005).
62. Mabbott DJ, Spiegler BJ, Greenberg ML et al. Serial evaluation of academic and behavioral outcome after treatment with cranial radiation in childhood. J. Clin. Oncol. 23, 2256-2263 (2005).
63. Ris MD, Packer R, Goldwein J et al. Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children's Cancer Group study. J. Clin. Oncol. 19, 3470-3476 (2001).
64. Jakacki RI, Feldman H, Jamison C et al. A pilot study of preirradiation chemotherapy and 1800 cGy craniospinal irradiation in young children with medulloblastoma. Int. J. Radiat. Oncol. Biol. Phys. 60, 531-536 (2004).
65. Kieffer-Renaux V, Viguier D, Raquin MA et al. Therapeutic schedules influence the pattern of intellectual decline after irradiation of posterior fossa tumors. Pediatr. Blood Cancer 45, 814-819 (2005).
66. Merchant TE, Mulhern RK, Krasin MJ et al. Preliminary results from a Phase II trial of conformal radiation therapy and evaluation of radiation-related CNS effects for pediatric patients with localized ependymoma. J. Clin. Oncol. 22, 3156-3162 (2004).
67. Norrell H, Wilson C. Brain tumor chemotherapy with methotrexate given intrathecally. A new technique. JAMA 201, 93-95 (1967).
68. Rosen G, Ghavimi F, Nirenberg A et al. High-dose methotrexate with citrovorum factor rescue for the treatment of central nervous system tumors in children. Cancer Treat. Rep. 61, 681-690 (1977).
69. Allen JC, Walker R, Rosen G. Preradiation high-dose intravenous methotrexate with leucovorin rescue for untreated primary childhood brain tumors. J. Clin. Oncol. 6, 649-653 (1988).
70. Vezmar S, Becker A, Bode U, Jaehde U. Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy 49, 92-104 (2003).
71. Butler RW, Hill JM, Steinherz PG et al. Neuropsychologic effects of cranial irradiation, intrathecal methotrexate, and systemic methotrexate in childhood cancer. J. Clin. Oncol. 12, 2621-2629 (1994).
72. Riva D, Giorgi C, Nichelli F et al. Intrathecal methotrexate affects cognitive function in children with medulloblastoma. Neurology 59, 48-53 (2002).
73. Shapiro WR, Chernik NL, Posner JB. Necrotizing encephalopathy following intraventricular instillation of methotrexate. Arch. Neurol. 28, 96-102 (1973).
74. Haykin M, Gorman M, van Hoff J et al. Diffusion-weighted MRI correlates of subacute methotrexate-related neurotoxicity. J. Neurooncol. 76, 153-157 (2006).
75. Duffner PK, Krischer JP, Horowitz ME et al. Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: a Pediatric Oncology Group Study. Ann. Neurol. 44, 313-316 (1998).
76. Ellison D. Classifying the medulloblastoma: insights from morphology and molecular genetics. Neuropathol. Appl. Neurobiol. 28, 257-282 (2002).
77. Kleihues P, Louis DN, Scheithauer BW et al. The WHO classification of tumors of the nervous system. J. Neuropathol. Exp. Neurol. 61, 215-225 (2002).
78. Pietsch T, Taylor MD, Rutka JT. Molecular pathogenesis of childhood brain tumors. J. Neurooncol. 70, 203-215 (2004).
79. Pomeroy SL, Tamayo P, Gaasenbeek M et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415, 436-442 (2002).
80. Brandes AA, Paris MK, Basso U. Medulloblastomas: do molecular and biologic markers indicate different prognoses and treatments? Expert Rev. Anticancer Ther. 3, 615-620 (2003).